☆ 4.4 Editorial Material

Gene Therapy Continues to Make Progress: Clinical and Regulatory Perspectives

CURRENT GENE THERAPY (2009)

Journal

CURRENT GENE THERAPY

Volume 9, Issue 5, Pages 327-328

Publisher

BENTHAM SCIENCE PUBL LTD

DOI: 10.2174/156652309789753374

Keywords

-

Categories

Genetics & Heredity

Funding

NINDS NIH HHS [R01 NS061107, R01 NS057711] Funding Source: Medline
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061107, R01NS057711] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Immunology

Immunomodulation in the Treatment of Periodontitis: Progress and Perspectives

Bo Yang, Xuefei Pang, Zhipeng Li, Zhuofan Chen, Yan Wang

Summary: In the treatment of periodontitis, modulating the immune microenvironment is crucial for preventing pathogen invasion and promoting periodontal regeneration. Utilizing new anti-inflammatory therapies can help generate viable local immune microenvironment, promoting tissue repair.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Current status and perspectives of regulatory T cell-based therapy

Guojun Qu, Jieqiong Chen, Yangyang Li, Yaqin Yuan, Rui Liang, Bin Li

Summary: CD4(+)FOXP3(+) regulatory T (Treg) cells play a vital role in maintaining immune homeostasis, and Treg cell-based therapies have shown promise in various diseases. Current challenges in Treg cell therapy include emerging clinical trials like CAR-Treg cell therapy and new strategies in engineering Treg cells.

JOURNAL OF GENETICS AND GENOMICS (2022)

Add to Collection

Review Genetics & Heredity

AAV-vector based gene therapy for mitochondrial disease: progress and future perspectives

Allison R. Hanaford, Yoon-Jae Cho, Hiroyuki Nakai

Summary: Mitochondrial diseases are rare disorders caused by gene mutations and result in defects in mitochondrial function. Effective treatments are currently lacking. Adeno-associated virus (AAV) gene replacement therapy has shown potential for treating mitochondrial diseases.

ORPHANET JOURNAL OF RARE DISEASES (2022)

Add to Collection

Review Cell Biology

Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy

Tianxia Lan, Li Chen, Xiawei Wei

Summary: Recent research has shown that the crucial components of cancer-related inflammation interact in a coordinated system to influence cancer development, offering new insights for potential anticancer therapies. Gene therapy targeting inflammatory cytokines is considered the most efficient approach for modulating the inflammatory microenvironment in cancer therapy. This manuscript provides a comprehensive review of the relationship between inflammation and cancer development, focusing specifically on inflammatory cytokines, and summarizes clinical trials for gene therapy targeting inflammatory cytokines in cancer treatment, as well as future perspectives on new gene-editing technology and novel gene delivery systems.

CELLS (2021)

Add to Collection

Review Biotechnology & Applied Microbiology

Gene Therapy in Orthopaedics: Progress and Challenges in Pre-Clinical Development and Translation

Rachael S. Watson-Levings, Glyn D. Palmer, Padraic P. Levings, E. Anthony Dacanay, Christopher H. Evans, Steven C. Ghivizzani

Summary: Gene-based treatment approaches are being investigated in orthopaedics for various pathologic conditions of the skeletal connective tissues and structures. The delivery of coding sequences for biologic agents to cells shows potential in enhancing tissue repair and inhibiting degenerative diseases.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2022)

Add to Collection

Article Materials Science, Biomaterials

Rational Designs at the Forefront of Mitochondria-Targeted Gene Delivery: Recent Progress and Future Perspectives

Naoto Yoshinaga, Keiji Numata

Summary: Mitochondria are crucial for cellular metabolism and energy production, and mutations in mitochondrial DNA can lead to inherited diseases. Strategies targeting mitochondria for gene therapy have been developed, but further research and optimization are needed.

ACS BIOMATERIALS SCIENCE & ENGINEERING (2022)

Add to Collection

Review Immunology

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Manasi P. Jogalekar, Ramya Lakshmi Rajendran, Fatima Khan, Crismita Dmello, Prakash Gangadaran, Byeong-Cheol Ahn

Summary: CAR-T cell therapy is a promising immune cell therapy for cancer, showing remarkable clinical responses in B-cell leukemia or lymphoma. However, it still faces challenges in treating other hematological and solid tumor malignancies, including severe toxicities and limited anti-tumor efficacy. This review discusses innovative CAR T-cell strategies to improve treatment outcomes and addresses the current challenges and new developments in CAR T-cell therapy.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Oncology

Gastric cancer treatment: recent progress and future perspectives

Wen-Long Guan, Ye He, Rui-Hua Xu

Summary: Gastric cancer is a common malignancy diagnosed at advanced stages due to subtle symptoms and low screening rates. Systemic therapies like chemotherapy, targeted therapy, and immunotherapy have advanced significantly. Perioperative chemotherapy is the standard for resectable GC. Targeted therapy and immunotherapy are being investigated for perioperative or adjuvant settings. Notable advancements have been made in immunotherapy and biomarker-directed therapies for metastatic disease. Molecular biomarkers like PD-L1, MSI, and HER2 help identify patients who may benefit from immunotherapy or targeted therapy. Molecular diagnostics enable the characterization of GC genetic profiles and the identification of potential targets. This review summarizes research progress, discusses individualized strategies, and presents future perspectives in systemic treatment for GC.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Add to Collection

Review Clinical Neurology

Viral gene therapy for paediatric neurological diseases: progress to clinical reality

Riccardo Privolizzi, Wing Sum Chu, Maha Tijani, Joanne Ng

Summary: In the era of genomic medicine, the diagnoses of rare paediatric neurological diseases are increasing, leading to a rise in gene therapy development. However, this comes with high risks. Gene therapy is seen as a potential single-dose cure, but its safety and efficacy still need further validation.

DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2021)

Add to Collection

Review Immunology

Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges

Tobias Riet, Markus Chmielewski

Summary: CAR T-cell therapy has revolutionized oncology and holds potential for treating autoimmune diseases. The development of antigen-specific receptors through genetic engineering of regulatory T cells (Tregs) is a logical step to improve their therapeutic potency. Preclinical studies have shown promising immune modulating properties of CAR Tregs in mouse models, but concerns remain regarding target selectivity, suppressive functions, phenotype stability, and safety aspects.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Biochemical Research Methods

Progress and Perspectives in the Development of Lentiviral Vector Producer Cells

Mariana Ferreira, Elisa T. Cabral, Ana Sofia Coroadinha

Summary: Gene therapy has proven effective in treating diseases after two decades of clinical trials, with lentiviral vectors being widely used to deliver genetic material. Recent approvals of gene therapy products highlight the necessity to improve bioprocess manufacturing, while establishing stable LV producer cell lines presents challenges.

BIOTECHNOLOGY JOURNAL (2021)

Add to Collection

Article Engineering, Environmental

Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives

Ziwei Jing, Qiuzheng Du, Xiaojian Zhang, Yu Zhang

Summary: This article summarizes the current development status of cancer nanomedicines, focusing on the latest progress in various treatment modalities, and discusses the challenges faced by cancer nanomedicines, proposing several prospects based on research experience.

CHEMICAL ENGINEERING JOURNAL (2022)

Add to Collection

Review Chemistry, Physical

Nanomaterial-based strategies in antimicrobial applications: Progress and perspectives

Yi Zhao, Long Chen, Yanan Wang, Xinyu Song, Keyang Li, Xuefeng Yan, Liangmin Yu, Zhiyu He

Summary: Nanomaterial-based antimicrobial strategies have emerged as novel and promising tools to combat lethal bacteria and recalcitrant biofilm by evading existing drug resistance-related mechanisms.

NANO RESEARCH (2021)

Add to Collection

Review Immunology

Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer

Xin Jin, Zhaorui Liu, Dongxiao Yang, Kai Yin, Xusheng Chang

Summary: Gastric carcinoma is a common form of solid tumor and is the third leading cause of death worldwide. The lack of obvious symptoms makes it difficult to detect gastric cancer at earlier stages, leading to a poor prognosis. However, recent advances in understanding the microenvironment of cancer have significantly promoted the development of immunotherapy for advanced gastric cancer. Immunotherapy has shown robust efficacy and tolerable toxicity compared to traditional therapies, making it a popular novel strategy for the treatment of advanced gastric cancer.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations

Laura I. Salazar-Fontana

Summary: Cell and Gene Therapy Products (CGT) are a novel and complex group of biotherapeutics developed to treat specific conditions with limited or no effective treatments. A regulatory risk-based approach is necessary to define a sound development plan and enable a benefit:risk analysis aligned with the characteristics of each CGT product.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion

Andrea Comba, Patrick J. Dunn, Phillip E. Kish, Padma Kadiyala, Alon Kahana, Maria G. Castro, Pedro R. Lowenstein

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2020)

Add to Collection

Article Multidisciplinary Sciences

Purine metabolism regulates DNA repair and therapy resistance in glioblastoma

Weihua Zhou, Yangyang Yao, Andrew J. Scott, Kari Wilder-Romans, Joseph J. Dresser, Christian K. Werner, Hanshi Sun, Drew Pratt, Peter Sajjakulnukit, Shuang G. Zhao, Mary Davis, Barbara S. Nelson, Christopher J. Halbrook, Li Zhang, Francesco Gatto, Yoshie Umemura, Angela K. Walker, Maureen Kachman, Jann N. Sarkaria, Jianping Xiong, Meredith A. Morgan, Alnawaz Rehemtualla, Maria G. Castro, Pedro Lowenstein, Sriram Chandrasekaran, Theodore S. Lawrence, Costas A. Lyssiotis, Daniel R. Wahl

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Medicine, Research & Experimental

Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice

Padma Kadiyala, Stephen Carney, Jessica C. Gauss, Maria B. Garcia-Fabiani, Santiago Haase, Mahmoud S. Alghamri, Felipe J. Nunez, Yayuan Liu, Minzhi Yu, Ayman Taher, Fernando M. Nunez, Dan Li, Marta B. Edwards, Celina G. Kleer, Henry Appelman, Yilun Sun, Lili Zhao, James J. Moon, Anna Schwendeman, Pedro R. Lowenstein, Maria G. Castro

Summary: The study focuses on glioma subtypes harboring mIDH1, TP53, and ATRX inactivation. In a mouse model, inhibition of D-2HG in combination with radiation and temozolomide (IR/TMZ) led to increased survival and anti-glioma immunological memory, which was enhanced by anti-PDL1 immune checkpoint blockade resulting in complete tumor regression in 60% of mice. This combination strategy reduced T cell exhaustion and favored memory CD8(+) T cell generation.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Review Neurosciences

Current Approaches for Glioma Gene Therapy and Virotherapy

Kaushik Banerjee, Felipe J. Nunez, Santiago Haase, Brandon L. McClellan, Syed M. Faisal, Stephen V. Carney, Jin Yu, Mahmoud S. Alghamri, Antonela S. Asad, Alejandro J. Nicola Candia, Maria Luisa Varela, Marianela Candolfi, Pedro R. Lowenstein, Maria G. Castro

Summary: Glioblastoma is a challenging brain tumor with poor prognosis, and gene therapy is considered a promising approach to overcome treatment barriers such as drug delivery inefficiency and tumor microenvironment. It involves modifying the genetic make-up of target cells and utilizing viral or non-viral delivery vehicles for specific therapeutic molecule delivery. Various gene therapy approaches are being developed to enhance immune responses, normalize angiogenesis, and improve anti-tumor efficacy, with potential concerns regarding off-target effects and efficiency.

FRONTIERS IN MOLECULAR NEUROSCIENCE (2021)

Add to Collection

Article Clinical Neurology

CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway

Elisabet Ampudia-Mesias, Francisco Puerta-Martinez, Miurel Bridges, David Zellmer, Andrew Janeiro, Matt Strokes, Yuk Y. Sham, Ayman Taher, Maria Castro, Christopher L. Moertel, G. Elizabeth Pluhar, Michael R. Olin

Summary: Numerous therapies aimed at driving an effective anti-glioma response have been employed over the last decade, with the study finding that CD200AR-L can modulate the immune response to glioblastoma through the DAP10 and 12 pathways, leading to increased survival rates in an intracranial GBM model. This provides a novel strategy for modulating immune checkpoints in immunotherapy currently being analyzed in phase I adult trial.

NEUROTHERAPEUTICS (2021)

Add to Collection

Correction Clinical Neurology

CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway (Apr, 10.1007/s13311-021-01038-1, 2021)

Elisabet Ampudia-Mesias, Francisco Puerta-Martinez, Miurel Bridges, David Zellmer, Andrew Janeiro, Matt Strokes, Yuk Y. Sham, Ayman Taher, Maria G. Castro, Christopher L. Moertel, G. Elizabeth Pluhar, Michael R. Olin

NEUROTHERAPEUTICS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments

Mahmoud S. Alghamri, Brandon L. McClellan, Margaret S. Hartlage, Santiago Haase, Syed Mohd Faisal, Rohit Thalla, Ali Dabaja, Kaushik Banerjee, Stephen V. Carney, Anzar A. Mujeeb, Michael R. Olin, James J. Moon, Anna Schwendeman, Pedro R. Lowenstein, Maria G. Castro

Summary: Gliomas, particularly glioblastomas, are highly aggressive and lethal cancers with unique molecular characteristics and genetic signatures. The interactions between tumor cells and immune cells in the tumor microenvironment play a critical role in glioma progression. Understanding the impact of inflammation and potential pharmacological interventions targeting neuro-inflammation are important for improving outcomes in glioma patients.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Review Oncology

Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies

Maria B. Garcia-Fabiani, Santiago Haase, Andrea Comba, Stephen Carney, Brandon McClellan, Kaushik Banerjee, Mahmoud S. Alghamri, Faisal Syed, Padma Kadiyala, Felipe J. Nunez, Marianela Candolfi, Antonela Asad, Nazareno Gonzalez, Marisa E. Aikins, Anna Schwendeman, James J. Moon, Pedro R. Lowenstein, Maria G. Castro

Summary: High grade gliomas, malignant brain tumors, have a poor prognosis with current standard of care. Immunotherapies show promise in pre-clinical studies but have not translated successfully to clinical benefits for glioma patients. Further research and development are needed to improve treatment outcomes.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications

Andrea Comba, Syed M. Faisal, Maria Luisa Varela, Todd Hollon, Wajd N. Al-Holou, Yoshie Umemura, Felipe J. Nunez, Sebastien Motsch, Maria G. Castro, Pedro R. Lowenstein

Summary: Glioblastomas are the most common and aggressive tumors of the central nervous system, characterized by heterogeneity at histological, cellular, genomic, and dynamic levels. This heterogeneity is suggested to arise from organized and dynamic attributes, favoring malignancy and influencing treatment regimens.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy

Mahmoud S. Alghamri, Brandon L. McClellan, Ruthvik P. Avvari, Rohit Thalla, Stephen Carney, Margaret S. Hartlage, Santiago Haase, Maria Ventosa, Ayman Taher, Neha Kamran, Li Zhang, Syed Mohd Faisal, Felipe J. Nunez, Maria Belen Garcia-Fabiani, Wajd N. Al-Holou, Daniel Orringer, Shawn Hervey-Jumper, Jason Heth, Parag G. Patil, Karen Eddy, Sofia D. Merajver, Peter J. Ulintz, Joshua Welch, Chao Gao, Jialin Liu, Gabriel Nunez, Dolores Hambardzumyan, Pedro R. Lowenstein, Maria G. Castro

Summary: The efficacy of immune-stimulatory gene therapy is enhanced in mIDH1 gliomas due to the reprogramming of infiltrating myeloid cells, mainly non-suppressive neutrophils and pre-neutrophils, in the tumor microenvironment. This reprogramming is triggered by granulocyte colony-stimulating factor (G-CSF) secreted by mIDH1 glioma stem/progenitor-like cells, leading to non-inhibitory myeloid cells within the tumor microenvironment and enhancing the therapy's effectiveness.

SCIENCE ADVANCES (2021)

Add to Collection

Editorial Material Pharmacology & Pharmacy

CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors

Christopher Moertel, Francisco Martinez-Puerta, Grace G. Elizabeth Pluhar, Maria Graciela Castro, Michael Olin

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Gene Therapy for High Grade Glioma: The Clinical Experience

Maria Luisa Varela, Andrea Comba, Syed M. Faisal, Anna Argento, Andrea Franson, Marcus N. Barissi, Sean Sachdev, Maria G. Castro, Pedro R. Lowenstein

Summary: High-grade gliomas (HGG) are the most common malignant primary brain tumors in adults, with a median survival of 18 months. Despite the standard treatment protocol remaining unchanged since 2005, gene therapy has shown promise in treating HGG. Clinical trials using viral and non-viral vectors have demonstrated safety and potential efficacy in increasing immune response and tumor cell destruction. Further analysis of these trials is expected to lead to the development of new treatment protocols and combinations to improve HGG prognosis.

EXPERT OPINION ON BIOLOGICAL THERAPY (2023)

Add to Collection

Review Medicine, Research & Experimental

Impact of epigenetic reprogramming on antitumor immune responses in glioma

Brandon L. McClellan, Santiago Haase, Felipe J. Nunez, Mahmoud S. Alghamri, Ali A. Dabaja, Pedro R. Lowenstein, Maria G. Castro

Summary: Epigenetic remodeling is a key factor in glioma progression, contributing to gliomagenesis, tumor progression, and responses to immunotherapies. This remodeling involves changes in histone modifications, chromatin structure, and DNA methylation driven by mutations in genes such as H3C1, H3F3A, IDH1/2, ATRX, and others. Recent studies have focused on understanding the role of epigenetic alterations in shaping the tumor microenvironment (TME) and how therapies targeting epigenetic dysregulation affect the immune response and outcomes in glioma. The link between epigenetic remodeling and the glioma TME provides insights for the development of epigenetic-targeting therapies to improve antitumor immune response.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Add to Collection

Article Oncology

A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1

Diana Shah, Andrea Comba, Syed M. Faisal, Padma Kadiyala, Gregory J. Baker, Mahmoud S. Alghamri, Robert Doherty, Daniel Zamler, Gabriel Nunez, Maria G. Castro, Pedro R. Lowenstein

Summary: The study demonstrates that miR-1983 released by glioma can activate TLR7, leading to the activation of NK cells through IFN-beta, and ultimately resulting in the eradication of glioma.

ONCOIMMUNOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells

Md Nabiul Hasan, Lanxin Luo, Dawei Ding, Shanshan Song, Mohammad Iqbal H. Bhuiyan, Ruijia Liu, Lesley M. Foley, Xiudong Guan, Gary Kohanbash, T. Kevin Hitchens, Maria G. Castro, Zhongling Zhang, Dandan Sun

Summary: The study found that blocking NHE1 activity in combination with Temozolomide (TMZ) in the treatment of glioblastoma may effectively stimulate anti-tumor immunity, increase T-cell infiltration, and enhance mitochondrial oxidative phosphorylation while reducing aerobic glycolysis. Selective deletion of the Nhe1 gene in GAMs can enhance sensitivity to anti-tumor immunotherapy.

THERANOSTICS (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.